Anti-7-Methylguanosine antibody [EPR20846-92] (BSA and Azide free)

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

The target 7-Methylguanosine also known as 7-methylguanosine cap or 7-methylguanosine triphosphate (7-methylguanosine GTP) plays an important role in RNA processing. It is a modified nucleotide with a mass of approximately 362.3 Da. This cap structure is found at the 5' end of eukaryotic messenger RNA (mRNA). The 7-methylguanosine cap is expressed in the nucleus where it is added co-transcriptionally to nascent mRNA transcripts. This modification enhances mRNA stability and regulates its export to the cytoplasm.

Biological function summary

This cap modification promotes ribosomal binding facilitating efficient translation initiation. The 7-methylguanosine cap is part of the cap-binding complex which includes other proteins like eIF4E. This complex protects RNA from degradation and aids in splicing 5' end processing and polyadenylation. The methylation of the guanine base forms a structure that recruits proteins essential for mRNA maturation and function. Without this modification mRNA would display reduced translational efficiency and be more susceptible to exonucleolytic decay.

Pathways

7-methylguanosine participates in the RNA processing and translation initiation pathways. It interacts with the eukaryotic translation initiation factor 4E (eIF4E) a critical player in the regulation of mRNA cap-dependent translation. The binding of eIF4E to the 7-methylguanosine cap is essential for assembly of the eIF4F complex. This complex drives the mRNA to the ribosome facilitating protein synthesis. Additionally this cap structure influences mRNA export and poly(A) tail formation connecting to the broader mRNA metabolic pathway and impacting gene expression regulation.

Associated diseases and disorders

Defects in the 7-methylguanosine cap can lead to improper mRNA processing and contribute to diseases like cancer and some congenital disorders. Dysregulation of cap-binding proteins such as eIF4E links to oncogenesis as these proteins can become overexpressed in cancers driving abnormal cell proliferation. Additionally cancer therapies often target these pathways to inhibit the translation of oncogenic mRNAs. Furthermore mutations or malfunctions in methylation enzymes can result in congenital developmental disorders as critical proteins necessary for normal growth and cellular function become deficient due to impaired mRNA translation.